Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer

Mechanisms Of Resistance ◽

Radioligand Therapy ◽

Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T

Endocrine Abstracts ◽

10.1530/endoabs.47.oc32 ◽

2016 ◽

Author(s):

Harshad R. Kulkarni ◽

Aviral Singh ◽

Christiane Schuchardt ◽

Karin Niepsch ◽

Richard P. Baum

Keyword(s):

Prostate Cancer ◽

Radioligand Therapy ◽

Castration Resistant ◽

A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177–labeled Prostate-specific Membrane Antigen–targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2021.03.004 ◽

2021 ◽

Author(s):

Mohammad S. Sadaghiani ◽

Sara Sheikhbahaei ◽

Rudolf A. Werner ◽

Kenneth J. Pienta ◽

Martin G. Pomper ◽

...

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

Meta Analysis ◽

Radioligand Therapy ◽

Castration Resistant ◽

Effects of 225Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: A meta-analysis

Journal of Nuclear Medicine ◽

10.2967/jnumed.121.262017 ◽

2021 ◽

pp. jnumed.121.262017

Author(s):

Dong Yun Lee ◽

Yong-il Kim

Keyword(s):

Prostate Cancer ◽

Meta Analysis ◽

Radioligand Therapy ◽

Castration Resistant ◽

Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy

Clinical Nuclear Medicine ◽

10.1097/rlu.0000000000003307 ◽

2020 ◽

Vol 45 (12) ◽

pp. 935-942 ◽

Cited By ~ 2

Author(s):

Swayamjeet Satapathy ◽

Bhagwant Rai Mittal ◽

Ashwani Sood

Keyword(s):

Prostate Cancer ◽

Survival Outcomes ◽

Radioligand Therapy ◽

Castration Resistant ◽

Predictors Of Response ◽

Visceral Metastases ◽

Is 177Lu-Prostate-Specific Membrane Antigen Radioligand Therapy Better Than Third-Line Systemic Treatment for Advanced Prostate Cancer?

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.06.1253 ◽

2017 ◽

Vol 99 (2) ◽

pp. E272

Author(s):

F. Von Eyben ◽

K. Kairemo ◽

T. Kiljunen ◽

T.K. Joensuu ◽

R. Baum ◽

...

Keyword(s):

Prostate Cancer ◽

Advanced Prostate Cancer ◽

Systemic Treatment ◽

Radioligand Therapy ◽

Third Line ◽

Specific Membrane ◽

Better Than

V1221 INTRAOPERATIVE USE OF A PROSTATE SPECIFIC MEMBRANE ANTIGEN-BASED FLUORESCENT IMAGING AGENT FOR PROSTATE CANCER IN A MOUSE MODEL

The Journal of Urology ◽

10.1016/j.juro.2011.02.879 ◽

2011 ◽

Vol 185 (4S) ◽

Cited By ~ 1

Author(s):

John Eifler ◽

Wasim Chowdhury ◽

Mark Castanares ◽

Catherine Foss ◽

Netto George ◽

...

Keyword(s):

Prostate Cancer ◽

Mouse Model ◽

Fluorescent Imaging ◽

Imaging Agent ◽

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Investigative and Clinical Urology ◽

10.4111/icu.20210097 ◽

2021 ◽

Vol 62 (6) ◽

pp. 650

Author(s):

William John Yaxley ◽

Rhiannon McBean ◽

David Wong ◽

David Grimes ◽

Paul Vasey ◽

...

Keyword(s):

Prostate Cancer ◽

Lymph Node ◽

Metastatic Prostate Cancer ◽

Radioligand Therapy ◽

177Lutetium prostate specific membrane antigen radioligand therapy of patients with metastatic castration-resistant prostate cancer

10.26226/morressier.5d778d875324a95faca51136 ◽

2019 ◽

Author(s):

Finn Edler von Eyben

Keyword(s):

Prostate Cancer ◽

Radioligand Therapy ◽

Castration Resistant ◽

Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG

Bioconjugate Chemistry ◽

10.1021/acs.bioconjchem.8b00292 ◽

2018 ◽

Vol 29 (7) ◽

pp. 2309-2315 ◽

Cited By ~ 18

Author(s):

Zhantong Wang ◽

Orit Jacobson ◽

Rui Tian ◽

Ronnie C. Mease ◽

Dale O. Kiesewetter ◽

...

Keyword(s):

Prostate Cancer ◽

Radioligand Therapy ◽

Radioligand Therapy With 177Lu–Prostate-Specific Membrane Antigen in a Patient With Non–Prostate-Specific Antigen–Secreting Metastatic Prostate Cancer

Clinical Nuclear Medicine ◽

10.1097/rlu.0000000000003208 ◽

2020 ◽

Vol 45 (10) ◽

pp. 789-791

Author(s):

Elahe Pirayesh

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Metastatic Prostate Cancer ◽

Specific Antigen ◽

Radioligand Therapy ◽